Corient Private Wealth
BCRX icon

Corient Private Wealth’s BioCryst Pharmaceuticals BCRX Stock Holding History

Corient Private Wealth’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.5M Buy
150,447
+54,980
+58% +$497K ﹤0.01% 1562
2026
Q1 		$909K Buy
95,467
+25,089
+36% +$195K ﹤0.01% 1709
2025
Q4 		$549K Sell
70,378
-397
-0.6% -$2.87K ﹤0.01% 1821
2025
Q3 		$537K Buy
+70,775
New +$589K ﹤0.01% 1760

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Corient Private Wealth's BCRX Position: Q2 2026 in Review

Corient Private Wealth increased its BioCryst Pharmaceuticals (BCRX) stake by 58% in Q2 2026, buying an estimated $497K and bringing the position to 150,447 shares worth $1.5M. The position accounts for ﹤0.01% of the portfolio, ranked #1562.

Corient Private Wealth first reported a position in BCRX in Q3 2025 and has held it in 4 quarters since. 319 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Corient Private Wealth held 150,447 shares of BioCryst Pharmaceuticals worth $1.5M as of Q2 2026.
  • Corient Private Wealth bought 54,980 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $497K.
  • BioCryst Pharmaceuticals made up ﹤0.01% of Corient Private Wealth's portfolio in Q2 2026, its #1562 holding.
  • Corient Private Wealth first reported a position in BioCryst Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • 319 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Corient Private Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.